Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs
- Conditions
- Rotavirus Vaccine
- Interventions
- Biological: RotarixBiological: RotaTeq
- Registration Number
- NCT02193061
- Lead Sponsor
- National Institute of Pediatrics, Mexico
- Brief Summary
Assess the immunological behavior of children from 2 months of age that receive one out of seven anti-rotavirus vaccination programs: Group 1 (routine schedule with two doses of RV1 - Rotarix plus sterile water) and Group 2 (routine schedule with three doses of RV5 - RotaTeq) versus Group 3 (one dose of monovalent vaccine followed by two doses of pentavalent vaccine), Group 4 (one dose of pentavalent vaccine followed by two doses of monovalent vaccine), Group 5 (two doses of pentavalent vaccine followed by a dose of monovalent vaccine), Group 6 (one dose of pentavalent vaccine followed by a dose of monovalent vaccine and a dose of pentavalent vaccine), and Group 7 (a dose of monovalent vaccine followed by a dose of pentavalent vaccine and a dose of monovalent vaccine) in children from Mexico City.
Secondary objectives
* To describe number and features of acute diarrheal disease (ADD) due to rotavirus displayed in the seven prevention schedules.
* To describe the adverse events temporarily associated with the seven prevention schedules.
Hypotheses The seroconversion percentages and geometric mean titers (GMT) of anti-rotavirus antibodies from Groups 3, 4, 5, 6 and 7 are not inferior to the seroconversion percentages and the GMTs induced in subjects that received the routine vaccination schedules with two doses of the monovalent vaccine and three doses of the pentavalent vaccine (Groups 1 and 2).
- Detailed Description
In this protocol we included 1498 at 6 to 8 weeks of age with a second visit at 2 months, a third visit at 4months four visit at 5 months after the first vaccination, ( 1st, second and 3erd visits for vaccine administration) phone calls every month and not schedule visits at the center when parents required and the last protocol visit was at one year of age This follow up to one year was to access security.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1498
- The subject is a boy or a girl 2 months ± one week old at the time of the first dose of the vaccine.
- The subject is considered to be healthy based on the clinical history and the physical examination.
- The subject has not received any anti-rotavirus vaccine.
- The parent/tutor fully understands the study's procedures and voluntarily accepts to participate and signs a written informed consent.
- The parent/tutor can meet the study's requirements, such as attending the programmed visits and filling in the journal.
- Written informed consent signed by the parent/tutor before any procedure.
- The subject has a background of serious allergic reaction to any of the vaccine's components.
- The subject has a digestive tract malformation or acute/chronic disease.
- The subject has some kind of immunodeficiency including HIV.
- The subject suffers from a haemato-oncological disease.
- The subject has been under treatment with an immunosuppressing medicine including prednisone for two or more weeks.
- The subject has received gamma-globulin or any other blood-derived product or its administration is programmed during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description ROTA 5 Rotarix two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix ROTA 1 Rotarix two doses of monovalent vaccine Rotarix followed by one dose of sterile water ROTA 3 Rotarix one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq ROTA 7 Rotarix a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix ROTA 4 RotaTeq one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix ROTA 7 RotaTeq a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix ROTA 3 RotaTeq one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq ROTA 5 RotaTeq two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix ROTA 6 Rotarix one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq ROTA 2 RotaTeq three doses of pentavalent vaccine RotaTeq ROTA 4 Rotarix one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix ROTA 6 RotaTeq one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
- Primary Outcome Measures
Name Time Method General Symptoms - Temperature subsequent 5 days since the vaccination day The subject temperature will be registered with a rectal thermometer during 5 days since the vaccination day in a diary card .
If the subject presents fever, the temperature will be recorded in a specific diary card section.
- Secondary Outcome Measures
Name Time Method Evacuation subsequent 30 days since the vaccination day The number of evacuations per day and their characteristics will be registered in a diary card
Trial Locations
- Locations (1)
National Instiute of Pediatrics
🇲🇽México City, D.f., Mexico